Myricetin directly targets JAK1 to inhibit cell transformation

Cancer Letters

Volumn 275, Issue 1, 2009, Pages 17-26

  Kumamoto, Takuma ^a   Fujii, Makoto ^a   Hou, De Xing ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

EGF; JAK1; JB6 cells; Myricetin; STAT3

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; JANUS KINASE 1; JANUS KINASE 2; KAEMPFEROL; MYRICETIN; PICEATANNOL; QUERCETIN; SERINE; STAT3 PROTEIN; TYROSINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; CELL TRANSFORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; DRUG BINDING; DRUG PROTEIN BINDING; DRUG TARGETING; EX VIVO STUDY; GENETIC TRANSCRIPTION; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; ANTIOXIDANTS; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; DNA; EPIDERMAL GROWTH FACTOR; FLAVONOIDS; JANUS KINASE 1; KAEMPFEROLS; MICE; PHOSPHORYLATION; PROTEIN BINDING; QUERCETIN; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC;

EID: 58549107213     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.09.027     Document Type: Article

References (39)

1. Silva C.M. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 18 (2004) 8017-8023
2. Darnell Jr. J.E. STATs and gene regulation. Science 12 (1997) 1630-1635
3. Klampfer L. Signal transducers and activators of transcription (STATs): novel targets of chemopreventive and chemotherapeutic drugs. Curr. Cancer Drug Targets 6 (2006) 107-121
4. Chan K.S., Carbajal S., Kiguchi K., Clifford J., Sano S., and DiGiovanni J. Epidermal growth factor receptor-mediated activation of Stat3 during multistage skin carcinogenesis. Cancer Res. 1 (2004) 2382-2389
5. Chan K.S., Sano S., Kiguchi K., Anders J., Komazawa N., Takeda J., and DiGiovanni J. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J. Clin. Invest. 114 (2004) 720-728
6. Yamaoka K., Saharinen P., Pesu M., Holt V.E., Silvennoinen O., and O'Shea J.J. The Janus kinases. Genome Biol. 253 (2004)
7. Rane S.G., and Reddy E.P. Janus kinases: components of multiple signaling pathways. Oncogene 19 (2000) 5662-5679
8. Turkson J., and Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 27 (2000) 6613-6626
9. Sebastian S., Settleman J., Reshkin S.J., Azzariti A., Bellizzi A., and Paradiso A. The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim. Biophys. Acta 1766 (2006) 120-139
10. Oda K., Matsuoka Y., Funahashi A., and Kitano H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol. Syst. Biol. 1 (2005) 0010
11. Lin J., Zhang S.M., Wu K., Willett W.C., Fuchs C.S., and Giovannucci E. Flavonoid intake and colorectal cancer risk in men and women. Am. J. Epidemiol. 1 (2006) 644-651
12. Ong K.C., and Khoo H.E. Biological effects of myricetin. Gen. Pharmacol. 29 (1997) 121-126
13. Ko C.H., Shen S.C., Hsu C.S., and Chen Y.C. Mitochondrial-dependent, reactive oxygen species-independent apoptosis by myricetin: roles of protein kinase C, cytochrome c, and caspase cascade. roles of protein kinase C, cytochrome c, and caspase cascade. Biochem. Pharmacol. 15 (2005) 913-927
14. Lu J., Papp L.V., Fang J., Rodriguez-Nieto S., Zhivotovsky B., and Holmgren A. Inhibition of Mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity. Cancer Res. 15 (2006) 4410-4418
15. Ko C.H., Shen S.C., Lee T.J., and Chen Y.C. Myricetin inhibits matrix metalloproteinase 2 protein expression and enzyme activity in colorectal carcinoma cells. Mol. Cancer Ther. 4 (2005) 281-290
16. Ichimatsu D., Nomura M., Nakamura S., Moritani S., Yokogawa K., Kobayashi S., Nishioka T., and Miyamoto K. Structure-activity relationship of flavonoids for inhibition of epidermal growth factor-induced transformation of JB6 Cl 41 cells. Mol. Carcinog. 46 (2007) 436-445
17. Lee K.M., Kang N.J., Han J.H., Lee K.W., and Lee H.J. Myricetin down-regulates phorbol ester-induced cyclooxygenase-2 expression in mouse epidermal cells by blocking activation of nuclear factor kappa B. J. Agric. Food Chem. 14 (2007) 9678-9684
18. Liu I.M., Tzeng T.F., Liou S.S., and Lan T.W. Myricetin, a naturally occurring flavonol, ameliorates insulin resistance induced by a high-fructose diet in rats. Life Sci. 10 (2007) 1479-1488
19. Lee K.W., Kang N.J., Rogozin E.A., Kim H.G., Cho Y.Y., Bode A.M., Lee H.J., Surh Y.J., Bowden G.T., and Dong Z. Myricetin is a novel natural inhibitor of neoplastic cell transformation and MEK1. Carcinogenesis 28 (2007) 1918-1927
20. Hou D.X., Kai K., Li J.J., Lin S., Terahara N., Wakamatsu M., Fujii M., Young M.R., and Colburn N. Anthocyanidins inhibit activator protein 1 activity and cell transformation: structure-activity relationship and molecular mechanisms. Carcinogenesis 25 (2004) 29-36
21. Tanigawa S., Fujii M., and Hou D.X. Action of Nrf2 and Keap1 in ARE-mediated NQO1 expression by quercetin. Free Radic. Biol. Med. 1 (2007) 1690-1703
22. Kamihira M., Nakazawa H., Kira A., Mizutani Y., Nakamura M., and Nakayama T. Interaction of tea catechins with lipid bilayers investigated by a quartz-crystal microbalance analysis. Biosci. Biotechnol. Biochem. 72 (2008) 1372-1375
23. Cen X., Nitta A., Ohya S., Zhao Y., Ozawa N., Mouri A., Ibi D., Wang L., Suzuki M., Saito K., Ito Y., Kawagoe T., Noda Y., Ito Y., Furukawa S., and Nabeshima T. An analog of a dipeptide-like structure of FK506 increases glial cell line-derived neurotrophic factor expression through cAMP response element-binding protein activated by heat shock protein 90/Akt signaling pathway. J. Neurosci. 26 (2006) 3335-3344
24. Sato Y., Sagami I., and Shimizu T. Identification of caveolin-1-interacting in neuronal nitric-oxide synthase. J. Biol. Chem. 279 (2004) 8827-8836
25. Lim C.P., and Cao X. Serine phosphorylation and negative regulation of Stat3 by JNK. J. Biol. Chem. 274 (1999) 31055-31061
26. Park C.M., Park M.J., Kwak H.J., Lee H.C., Kim M.S., Lee S.H., Park I.C., Rhee C.H., and Hong S.I. Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways. Cancer Res. 66 (2006) 8511-8519
27. Potter G.A., Patterson L.H., Wanogho E., Perry P.J., Butler P.C., Ijaz T., Ruparelia K.C., Lamb J.H., Farmer P.B., Stanley L.A., and Burke M.D. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br. J. Cancer 4 (2002) 774-778
28. Alas S., and Bonavida B. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin. Cancer Res. 9 (2003) 316-326
29. Young M.R., Yang H.S., and Colburn N.H. Promising molecular targets for cancer prevention: AP-1, NF-kB and Pdcd4. Trends Mol. Med. 9 (2003) 36-41
30. Ermakova S., Choi B.Y., Choi H.S., Kang B.S., Bode A.M., and Dong Z. The intermediate filament protein vimentin is a new target for epigallocatechin gallate. J. Biol. Chem. 280 (2005) 16882-16890
31. Ermakova S.P., Kang B.S., Choi B.Y., Choi H.S., Schuster T.F., Ma W.Y., Bode A.M., and Dong Z. (-)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78. Cancer Res. 66 (2006) 9260-9269
32. Li M., He Z., Ermakova S., Zheng D., Tang F., Cho Y.Y., Zhu F., Ma W.Y., Sham Y., Rogozin E.A., Bode A.M., Cao Y., and Dong Z. Direct inhibition of insulin-like growth factor-I receptor kinase activity by (-)-epigallocatechin-3-gallate regulates cell transformation. Cancer Epidemiol. Biomark. Prev. 16 (2007) 598-605
33. Kang N.J., Lee K.W., Rogozin E.A., Cho Y.Y., Heo Y.S., Bode A.M., Lee H.J., and Dong Z. Equal, a metabolite of the soybean isoflavone daidzein, inhibits neoplastic cell transformation by targeting the MEK/ERK/p90RSK/activator protein-1 pathway. J. Biol. Chem. 282 (2007) 32856-32866
34. Lee K.W., Kang N.J., Heo Y.S., Rogozin E.A., Pugliese A., Hwang M.K., Bowden G.T., Bode A.M., Lee H.J., and Dong Z. Raf and MEK protein kinases are direct molecular targets for the chemopreventive effect of quercetin, a major flavonol in red wine. Cancer Res. 68 (2008) 946-955
35. Zykova TA., Zhu F., Zhai X., Ma W.Y., Ermakova S.P., Lee K.W., Bode A.M., and Dong Z. Resveratrol directly targets COX-2 to inhibit carcinogenesis. Mol. Carcinog. 47 (2008) 797-805
36. Kang N.J., Lee K.W., Lee DE., Rogozin E.A., Bode A.M., Lee H.J., and Dong Z. Cocoa procyanidins suppress transformation by inhibiting mitogen-activated protein kinase. J. Biol. Chem. 283 (2008) 20664-20673
37. Jorissen R.N., Walker F., Pouliot N., Garrett T.P., Ward C.W., and Burgess A.W. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp. Cell Res. 284 (2003) 31-53
38. Kil S.J., and Carlin C. EGF receptor residues leu(679), leu(680) mediate selective sorting of ligand-receptor complexes in early endosomal compartments. J. Cell. Physiol. 185 (2000) 47-60
39. Thien C.B., Walker F., and Langdon W.Y. RING finger mutations that abolish c-Cbl-directed polyubiquitination and downregulation of the EGF receptor are insufficient for cell transformation. Mol. Cell 7 (2001) 355-365